Armata Pharmaceuticals

What Armata Pharmaceuticals does

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant bacterial infections in humans. The company's lead clinical candidate, AP-SA02, is a fixed multi-phage cocktail administered intravenously as adjunct therapy for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA; AP-SA02 demonstrated an 88% clinical response rate at day 12 versus 58% for placebo with zero relapse in the treatment arm in the Phase 2a diSArm study, and is positioned to enter a pivotal Phase 3 superiority study in H2 2026 after receiving FDA Fast Track Designation and Qualified Infectious Disease Product (QIDP) status. A second program, AP-PA02, targets Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, with related candidate AP-PA03 in earlier development. Underlying the pipeline is a proprietary synthetic phage platform supported by published cryo-EM structural biology work (collaboration with University of Alabama at Birmingham, published in Communications Biology / Nature Portfolio) and a 56,000 square foot in-house cGMP manufacturing facility in Los Angeles commissioned in November 2025.

The company is pre-commercial and generates no product revenue; its operating revenue consists of grant and award income (notably $1.1 million in Q1 2026 from the Medical Technology Enterprise Consortium), while development is funded primarily through non-dilutive U.S. Department of Defense awards totaling $28.7 million through MTEC and a series of secured credit facilities from its majority owner Innoviva Strategic Opportunities LLC totaling over $130 million since 2020, including a $25 million facility executed in May 2026 maturing January 2029. Armata was formed in 2019 through the merger involving AmpliPhi Biosciences, is incorporated in Delaware with operational headquarters in Los Angeles and Marina del Rey, California, is led by CEO Dr. Deborah L. Birx (appointed July 2023), and serves an eventual patient population of hospitalized S. aureus bacteremia cases and chronic respiratory infection sufferers with high unmet need given rising antimicrobial resistance.

Name

Armata Pharmaceuticals

Legal name

Armata Pharmaceuticals, Inc.

Website

https://armatapharma.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity bacteriophage therapeutics for antibiotic-resistant bacterial infections, advancing lead candidate AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa respiratory infections in cystic fibrosis patients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Bacteriophage therapeutics
• Antibiotic-resistant infections
• Clinical-stage biotechnology
• Phage cocktail therapeutics
• Infectious disease biologics

Headquarters

HQ city

Marina Del Rey

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Grant and Award Revenue: Armata generates grant and award revenue from government and non-governmental sources. The company recognized $0.8 million in Q1 2026 from Medical Technology Enterprise Consortium cost-sharing for the AP-SA02 program. Historically, the company has received substantial non-dilutive funding from the U.S. Department of Defense for clinical development.
2. Pharmaceutical Product Sales (Future): Pre-commercial stage. The company is advancing bacteriophage therapeutics through clinical development toward regulatory approval. If approved, AP-SA02 and AP-PA02 would be commercialized as prescription biologics for treatment of antibiotic-resistant bacterial infections, generating product revenue through standard pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Armata Pharmaceuticals develops high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant bacterial infections. Its lead clinical candidate, AP-SA02, is a multi-phage cocktail administered intravenously for complicated Staphylococcus aureus bacteremia (including MRSA) and is advancing toward a Phase 3 superiority study. A second candidate, AP-PA02, targets Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-CF bronchiectasis patients. The company supports its pipeline with proprietary synthetic phage engineering technology and an in-house 56,000 sq ft cGMP manufacturing facility in Los Angeles.

Product overview

Armata Pharmaceuticals is a late clinical-stage biotechnology company developing a pipeline of high-purity, pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant bacterial infections. The company's product portfolio includes clinical candidates AP-SA02 (for Staphylococcus aureus bacteremia) and AP-PA02 (for Pseudomonas aeruginosa respiratory infections), along with manufacturing capabilities including a cGMP facility in Los Angeles. The company operates a proprietary bacteriophage-based technology platform using both natural and synthetic phage candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• AP-SA02 Fixed multi-phage cocktail administered intravenously as adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA; advancing toward Phase 3 superiority study after FDA End-of-Phase 2 alignment and QIDP and Fast Track designations.
• AP-PA02 Therapeutic phage cocktail targeting Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-CF bronchiectasis patients; includes phage P7-1 structurally characterized in collaboration with the University of Alabama at Birmingham.
• AP-PA03 Pipeline candidate related to the AP-PA02 program for Pseudomonas aeruginosa infections, part of Armata's pipeline of natural and synthetic phage candidates.
• cGMP Phage Manufacturing Facility State-of-the-art 56,000 square foot cGMP manufacturing facility in Los Angeles with clean rooms and quality control laboratories, producing high-purity bacteriophage therapeutics for clinical trials and potential commercialization.

Quantifiable outcome

• 88% clinical response rate at day 12 for AP-SA02 vs 58% for placebo in Phase 2a diSArm study
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of Alabama at BirminghamcoreStrategic or Co-development Partner · 4 May 2026Research collaboration with University of Alabama at Birmingham for structural characterization of phage P7-1, a component of the AP-PA02 phage cocktail. The study used cryo-electron microscopy to reveal phage architecture and has been published in Communications Biology (Nature Portfolio). This collaboration supports Armata's understanding of phage structure for engineering next-generation therapeutics.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Locus Biosciences: Clinical-stage company developing engineered bacteriophage products enhanced with CRISPR-Cas3 to target antibiotic-resistant pathogens — directly comparable in modality (engineered phage) and infectious-disease focus to Armata's pipeline.
• BiomX: Clinical-stage phage therapy company developing customized phage cocktails for chronic infections and microbiome-related diseases — comparable in phage-cocktail approach and infectious-disease focus, with both natural and engineered phage candidates.
• Phagelux: Clinical-stage phage-based biotherapeutics company developing products for antibiotic-resistant bacterial infections — directly comparable modality and therapeutic focus to Armata, with parallel pipeline approach.
• Intralytix: Commercial-stage phage technology company producing phage-based products for food safety, animal health, and human therapeutics — a peer in the broader bacteriophage space, though with a more diversified commercial focus than Armata's pure-play anti-infectives strategy.
• Eligo Bioscience: Developer of engineered phage-based precision medicines (Eligobiotics) for microbiome modulation and infectious disease — a direct phage-therapeutics peer, though earlier-stage than Armata, with overlapping technology approach.
• Adaptive Phage Therapeutics: Clinical-stage bacteriophage therapy company developing phage-based treatments for antibiotic-resistant infections, including S. aureus and P. aeruginosa — the most directly comparable peer to Armata given overlapping targets and modality.

Broad incumbents

• Cidara Therapeutics: Clinical-stage anti-infectives company developing immunotherapy-based approaches (Cloudbreak) and traditional antivirals/antifungals for serious infections — a broader anti-infectives peer with similar small-cap clinical-stage profile and FDA designation history.
• Nabriva Therapeutics: Commercial/clinical-stage anti-infectives company with approved antibiotic (XENLETA) for community-acquired bacterial pneumonia — a broader incumbent in the anti-infectives space with comparable size profile and target indications (serious bacterial infections).
• Iterum Therapeutics: Clinical-stage anti-infectives company developing oral and IV antibiotics for multi-drug resistant infections — comparable as a small-cap anti-infectives peer targeting similar hospital-treated resistant infections, though via traditional small-molecule approach rather than phage.

Others

• Entasis Therapeutics: Anti-infectives company developing targeted small-molecule antibiotics for drug-resistant infections, acquired by Innoviva in 2022 — a sibling entity under Armata's controlling shareholder, providing relevant peer benchmarks for anti-infectives development and Innoviva's broader strategic portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/armata-pharmaceuticals

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds17 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Armata Pharmaceuticals